Table 2

Summary of low and middle income country studies reporting MSM HIV care continuum or cascade data, returned by PubMed/Medline, 1990–2016

Country, locationPopulationYearStudy designSample sizeHIV+TestedDiagnosedLinkedPre-ARTOn ARTViral load undetectable
 Nn (%)n (%)n (%)n (%)n (%)n (%)n (%)
Brazil, Rio de Janeiro35 MSM, TGW2013–2014Cohort793 (s)793 –131 (16.5)95 (72.5)90 (68.7)80 (61.1)50 (38.2)
China, 15 cities34 MSM2010Cohort531 295 (p)76 628 (12.7)3024 (3.9)1999 (66.0)NANANA
India, 27 sites36 37 MSM, PWID2012–2013RDS12 022 (s)1146 (9.5)NA344 (30.0)264 (23.0)252 (22.0)183 (16.0)115 (10.0)
Nigeria, Ajuba33 MSM2013–2014RDS706 (s)393 (55.7)393 (100)186 (47.6)70 (17.8)58 (14.8)37 (9.4)
Peru, national38 MSM, TGW2015Population613 080 (p)63 981 (10.4)NA15 355 (24.0)NA9981 (15.6)8701 13.6)7677 (12.0)
  • ART, antiretroviral treatment; MSM, men who have sex with men; NA, not available; p, population; PWID, person who injects drugs; RDS, respondent driven sampling; s, sample; TGW, transgender women.